Algeta is an oncology company developing treatments for bone metastases and disseminated tumor types. The company's lead product Alpharadin is targeting bone metastases which occur frequently in major cancers including hormone-refractory prostate cancer, breast, lung, kidney and thyroid. The treatment of bone metastases represents an area of high unmet medical need. Algeta's pipeline is built on world-leading, proprietary technology. Algeta is developing new, targeted cancer alpha-pharmaceuticals that harness the unique characteristics of alpha particle emitters to destroy cancer cells. Alpha particle emitters are potent, well tolerated and convenient to use. The first investment from Birk Venture/Investment was made in 2007. Go to Website Back to menu
Location: Norway, Oslo
Investors 1
| Date | Name | Website |
| - | Birk Ventu... | birkventur... |
Mentions in press and media 2
| Date | Title | Description |
| 28.09.2012 | Winners of Investor AllStars Awards 2012 announced | GP Bullhound and Vitesse Media reveal winners of prestigious awards, including the Investor of the Decade LONDON, UK; 28th September 2012 – The winners of the Investor AllStars Awards 2012 were revealed last night in a ceremony at the Park ... |
| - | Bayer completes voluntary takeover offer for Algeta | Bayer holds 98.2 % of Algeta shares after closing / Compulsory acquisition process planned in the coming days Leverkusen, March 6, 2014 – The Bayer Group has completed the voluntary takeover offer for Norwegian pharmaceutical company Alget... |